Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2023 investor letter. A copy of the same can be downloaded here.
1. Annualized bleeding rate was reduced by 91% in the fitusiran prophylaxis group compared to the bypassing agents on-demand group. 2. 5% of patients in the fitusiran group reported thromboembolic events; there were no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Hemophilia is marked by a deficiency in certain coagulation factors that make patients
Early Treatment can reduce joint damage in Severe Hemophilia A cases and by working together India can help to improve the lives of people with hemophilia TheHealthSite.com